JP2002173434A - Antiallergic composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain an antiallergic composition containing an aqueous extracted essence of Panax ginseng and oyster shell. SOLUTION: This antiallergic composition contains an aqueous essence of Panax ginseng and oyster shell, provides a characteristic synergistic action by simultaneously using these components and exhibits an excellent antiallergic action on animals including human. Especially, the antiallergic composition exhibits an excellent effect of preventing and alleviating symptoms of atopic dermatitis of infants, etc.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to an antiallergic composition, and more particularly, to an antiallergic composition for preventing or alleviating symptoms of allergic diseases such as atopic dermatitis.

[0002]

2. Description of the Related Art In general, allergy refers to a pathological process among effects of an antigen-antibody reaction on a living body.
Allergies are roughly classified into types I to IV. Among them, type I allergy induces the release of chemical mediators such as histamine and leukotriene from mast cells by an allergen that causes allergy, and these substances are smoothed. It is understood that this is a biological reaction that results in contraction of muscles and an increase in capillary permeability, and eventually damages surrounding tissues.

A typical example of a disease classified as type I allergy is atopic dermatitis, particularly atopic dermatitis in children. In recent years, the number of this disease has increased remarkably, and this tendency is associated with air pollution, changes in dietary habits (for example, the breakdown of fatty acid balance in the body due to excessive intake of linoleic acid), and in the use of drugs and cosmetics in humans. It is thought to be due to changes in the living environment caused by various synthetic compounds or the like which are frequently or rarely contacted, and increase in mental stress in daily life.

[0004] As a treatment for this atopic dermatitis,
Antiallergic agents containing synthetic compounds and the like have already been known, and examples include injections using histamine-added immunoglobulin or strong minophagen C, and external preparations mainly containing corticosteroids.

[0005] However, histamine-added immunoglobulin and potent minophagen C, which are used for the treatment and alleviation of allergic symptoms such as atopic dermatitis, are both administered as injections and are effective, but are accompanied by pain, so that they are painful. There was a problem that it was not suitable for the treatment of. The application of corticosteroids can also be expected to be effective, but undesired side effects (thinning and weakening of the skin,
Secondary adrenocortical dysfunction, etc.), which requires systematic medication under the supervision of a physician.
There is a problem that its use involves danger. Therefore, creation of an excellent composition capable of preventing or alleviating the symptoms of allergic diseases, particularly atopic dermatitis, without having the possibility of causing serious side effects has been desired.

[0006] JP-A-6-40931 describes an agent for enhancing the effect of treating adrenal corticosteroids on autoimmune diseases, which contains an extract of Ninjin Yoeito as an active ingredient. However, the present invention, when used in combination with corticosteroids, only enhances the therapeutic effect of corticosteroids on autoimmune diseases without increasing the dose of corticosteroids. Moreover, serious side effects of corticosteroids cannot be fundamentally circumvented even with this enhancer.

[0007]

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition which is effective even when administered orally, has a low possibility of side effects, and has an antiallergic effect.

[0008]

Means for Solving the Problems The present inventors have conducted intensive studies in view of the above problems, and as a result, have found that an excellent antiallergic effect can be obtained by blending ginseng extract and oyster shell. After further research, the present invention was completed. Therefore, the present invention is as follows.

(1) An antiallergic composition for preventing or alleviating the symptoms of allergic diseases, comprising an aqueous extract of ginseng (hereinafter, also simply referred to as ginseng extract) and oyster shells. (2) The antiallergic composition according to the above (1), wherein the ginseng is a ginseng. (3) The antiallergic composition according to (1) or (2), wherein the allergic disease is atopic dermatitis. (4) The antiallergic composition according to (1) or (2), wherein the allergic disease is an allergic disease involving type I allergy. (5) The antiallergic composition according to (4), wherein the allergic disease associated with type I allergy is atopic dermatitis. (6) The weight ratio of the ginseng extract to the oyster shell is such that the oyster shell is 50 to 100 parts by weight of the solid content of the ginseng extract.
The antiallergic composition according to any one of the above (1) to (5), which is 1000 parts by weight.

[0010] The antiallergic composition used in the present specification is one having a therapeutic or symptom-reducing effect on allergic diseases, especially allergic diseases involving type I allergy, and further having a preventive effect. It is.

According to the antiallergic composition of the present invention,
Diseases in which allergic symptoms are treated, prevented or alleviated include, for example, allergic diseases such as asthma and eczema, hay fever, hives, nasal allergy, drug allergies, and more specifically, atopic dermatitis, atopic bronchi Asthma, atopic diseases such as allergic rhinitis and the like,
Of these, it is particularly effective for atopic dermatitis and allergic rhinitis.

The ginseng that can be used in the present invention is not particularly limited as long as it has a synergistic effect on allergic diseases when combined with oyster hulls. For example, ginseng (Panax ginseng), tansin ginseng (Panax notoginseng), American ginseng (Panax quinquefolium), Chixets ginseng (Panax japonicus) and the like, among which ginseng is most preferred.

The ginseng in the present invention includes normally grown ginseng, a tissue culture product, a dried product thereof, and the like. The use of a tissue culture product and a dried product thereof is preferable from the viewpoint of quality stability. As the tissue culture product, a tissue culture product manufactured by Nitto Denko is preferable.

The ginseng extract of the present invention is obtained by extracting the above ginseng with an aqueous liquid.

Examples of the aqueous liquid include water itself, a mixed liquid of water and ethanol, and the like. As a mixture, the ratio of water in the aqueous liquid is 30 to 100%, preferably 80%.
〜100% are preferred.

The form of the ginseng at the time of extraction and the temperature of the aqueous liquid at the time of extraction are not particularly limited, but the extraction is preferably carried out at 60 ° C. or higher, preferably 80 ° C. or higher from the viewpoint of extraction efficiency. . In addition, the extraction time varies depending on the form of ginseng used (difference between whether it is raw or dried and difference in particle size due to pulverization) in consideration of its efficiency. 0.2 to 3 hours if raw 22 mesh, 22 to 400
When the dried product is a mesh, it is preferable to extract the dried product for 0.5 to 8 hours. The extract solution after the extraction may be used as it is, or may be used by concentrating it under reduced pressure and freeze-drying to obtain a powder.

In the case of extraction using only a solvent other than water as an extraction solvent, for example, only an organic solvent (such as an alcohol or a saturated hydrocarbon), the constituent ratio of the extracted extract component is different from the extraction using water. Therefore, since the composition ratio of the extracted component is significantly different from that of the extract using water, the extract is unsuitable for preventing or alleviating the symptoms of allergic diseases, particularly atopic dermatitis. Not preferred.

The oyster shell used in the present invention is preferably used in the form of a powder, for example, Borei powder from the Japanese Pharmacopoeia. There is no problem in using oyster husk powder, which is a powder of borei other than the Japanese Pharmacopoeia. Oyster husk powder means oyster husk powdered using a suitable crusher or the like, but it is preferable to use powder that is as finely powdered as possible from the viewpoint of improving the absorption rate in the body. . The oyster shell powder may be preferably less than 22 mesh, more preferably less than 42 mesh, even more preferably less than 60 mesh. Oyster husks have a unique odor, and there is a problem that infants and the like cannot easily ingest oyster shells due to this unique odor. Considering this problem, it is preferable to reduce the odor by heating the oyster shell to about 200 ° C. to 300 ° C.

The antiallergic composition of the present invention can be obtained by blending the ginseng extract and oyster shell as described above. Here, the mixing ratio of the ginseng extract and the oyster shell is such that the oyster shell is about 50 to 1000 parts by weight, preferably 200 to 7 parts by weight, based on 100 parts by weight when the ginseng extract is solidified.
00 parts by weight, particularly preferably about 500 parts by weight.
When the compounding ratio is in this range, the effect of synergistically preventing or alleviating the allergic disease, in particular, the symptoms of atopic dermatitis is great.

When the antiallergic composition of the present invention is used as a medicament, it is formulated into a formulation known per se, for example, tablets, capsules, solutions and the like. At that time, other components may be appropriately blended in addition to the ginseng extract and the oyster shell depending on the use and the type of the preparation. As such a component, a known component may be used.

The antiallergic composition of the present invention can be applied to, for example, foods. In this case, the two components described above may be used as a powdered food as it is, or as a granular food or tableted food by tableting,
Furthermore, it may be prepared into confectionery such as cookies or biscuits, soft drinks, dairy products, staple foods and the like, and is not particularly limited and can be suitably applied to any food form. If necessary, it is also possible to prepare a composition containing the above-mentioned two components separately and take them simultaneously. In preparing these food forms, components known per se can be optionally added as necessary.

The amount of the composition containing the ginseng extract and the oyster shell of the present invention varies depending on conditions such as the age, body weight and degree of allergy of the user, and cannot be specified unconditionally. Any amount can be used as long as it is effective, but from the viewpoint of easy intake,
It may be appropriate to consume about 300 mg to 2500 mg of carrot extract and oyster shells in total, usually daily.

[0023]

EXAMPLES Hereinafter, the antiallergic composition of the present invention will be described in more detail with reference to Examples. However, the present invention is not limited at all by the following examples.

[Example 1] Preparation of drink 1 (Composition) (g) Ginseng extract (50% W / V extract manufactured by Nitto Denko) 0.6 Japanese Pharmacopoeia Borei powder 1.06 Fructose dextrose liquid sugar 10. 0 Citric acid 0.2 L-Ascorbic acid 0.02 Fragrance 0.1 Dye 0.1 Water 87.92 The above eight components were mixed to prepare a drink.

Example 2 Preparation of Drink 2 (Composition) (g) Ginseng extract (50% W / V extract manufactured by Nitto Denko) 0.15 Japan Pharmacopoeia Borei Powder 0.265 Fructose-glucose liquid sugar 0 Citric acid 0.2 L-Ascorbic acid 0.02 Fragrance 0.1 Dye 0.1 Water 89.17 The above eight components were uniformly mixed to prepare a drink.

[Example 3] Preparation of drink 3 (Composition) (g) Ginseng extract (50% W / V extract manufactured by Nitto Denko) 2.1 Japan Pharmacopoeia Borei Powder 1.855 Fructose-glucose liquid sugar 10. 0 Citric acid 0.2 L-Ascorbic acid 0.02 Fragrance 0.1 Dye 0.1 Water 85.63 The above eight components were uniformly mixed to prepare a drink.

[Comparative Example 1] Preparation of a drink containing no boray powder (composition) (g) Ginseng extract (50% W / V extract manufactured by Nitto Denko) 0.6 Fructose dextrose liquid sugar 10.0 Citric acid 0.2 L-ascorbic acid 0.02 Fragrance 0.1 Dye 0.1 Water 88.98 The above seven components were uniformly mixed to prepare a drink.

[Comparative Example 2] Preparation of a drink containing no ginseng extract (Composition) (g) Borei powder, Japanese Pharmacopoeia 1.06 Fructose-glucose liquid sugar 10.0 Citric acid 0.2 L-Ascorbic acid 0 .02 Fragrance 0.1 Dye 0.1 Water 88.52 The above seven components were uniformly mixed to prepare a drink.

[Comparative Example 3] Preparation of a drink containing neither ginseng extract nor boray powder (composition) (g) Fructose dextrose liquid sugar 10.0 citric acid 0.2 L-ascorbic acid 0.02 flavor 0 1 Dye 0.1 Water 89.58 The above six components were uniformly mixed to prepare a drink.

[Test Example 1] Among the drinks of Examples 1 to 3 and Comparative Examples 1 to 3, 18 men and women aged 6 to 12 who are allergic and exhibit atopic dermatitis symptoms
First, about the thing of Example 1, every day, one day after breakfast
Ingestion was continued for 8 weeks, followed by Example 2, Example 3, Comparative Example 1, Comparative Example 2, and Comparative Example 3 in the same order as in Example 1. A four week blank period was provided for each sample ingestion. Each subject was asked about "whether or not atopic dermatitis had developed" 8 weeks after the start of ingestion of each drink. Table 1 shows the number of respondents as test results.

[0031]

[Table 1]

As is evident from the results in Table 1, continuous ingestion of ginseng extract alone or continuous intake of boray powder alone could hardly suppress the onset of atopic cortical inflammation. It can be seen that, when the extract and the oyster shell powder were continuously taken simultaneously, the onset of atopic dermatitis was successfully suppressed.

Test Example 2 An NC mouse (NC / NgaTnd) widely used as an atopic dermatitis model animal
A pharmacological test was performed using Crj). 8 Sensitized mice by applying 2,4,6-trinitrochlorobenzene solution to aged mice. After 4 days, the back was shaved and atopically treated with 2,4,6-trinitrochlorobenzene solution again. Induced skin irritations. Thereafter, the induction was repeated once a week, for a total of four times. On the day before the third induction, the groups were divided using a computer so that the scores of dermatitis and the average body weight of each group (12 mice in one group) were almost the same. The administration of each sample was started on the same day as the grouping was performed. Sample A is a dispersion in which 12.5 mg of ginseng extract solids (manufactured by Nitto Denko) and 16.6 mg of Borei powder of the Japanese Pharmacopoeia are dispersed in 1 ml of water, and sample B is 1
A dispersion in which 2.5 mg of ginseng extract solids (manufactured by Nitto Denko) was dispersed in 1 ml of water, sample C was 16.6.
mg of Borei powder in Japanese Pharmacopoeia were dispersed in 1 ml of water, physiological saline alone was used as a negative control, and prednisolone ointment (manufactured by Maruishi Pharmaceutical) was used as a positive control. Samples A, B and C and physiological saline were orally administered at a dose of 10 ml / kg (body weight) once a day. The prednisolone ointment was applied once every two days (one application amount was 90 mg / animal). Regarding the scores of dermatitis, pruritus, redness or bleeding, edema, abrasion or tissue loss, crusting or dryness were respectively evaluated as 0 points for no symptoms, 1 point for mild, and 2 points for moderate.
The points and altitudes were determined to be 3 points, and the average value (divided by 12) and the standard deviation of the total points evaluated for each item were determined to be the dermatitis score.

As a result of evaluating this test based on the dermatitis score 15 days after the start of administration of the sample, the score of the group administered with physiological saline was 8.2 ± 0.4, and the score of the group administered with prednisolone ointment was 4.3 ±. 0.44, the score value of the sample A administration group was 5.0 ± 0.37, the score value of the sample B administration group was 8.1 ± 0.55, and the score value of the sample C administration group was 8.0 ± 0. It was 61.

On the other hand, the average body weight of the mice on the day of administration was 24 g ± 5% in each group, and the average body weight of mice on the day of the test evaluation (15 days after administration) was 22 g ± 5% only in the prednisolone administration group. , All other groups were 24 g ±
5%.

Test Example 3 The same test as in Test Example 2 was performed. However, instead of Sample A in Test Example 2, 12.5 mg of ginseng extract (manufactured by Nitto Denko) and 6.25 mg of Japanese Pharmacopoeia Borei Powder were used as Sample L.
of a dispersion obtained by dispersing 12.5 mg of ginseng extract (manufactured by Nitto Denko) and 125 mg of Borei powder of the Japanese Pharmacopoeia in 1 ml of water. Two samples were tested as alternatives to sample A.

As a result of evaluating this test based on the dermatitis score 15 days after the start of the administration of the sample, the score of the group administered with physiological saline was 8.3 ± 0.5, and the score of the group administered with prednisolone ointment was 4.2 ±. 0.48, the score of the sample L administration group was 5.1 ± 0.41, the score of the sample H administration group was 4.9 ± 0.47, and the score of the sample B administration group was 8.2 ± 0. 52, the score value of the sample C administration group was 8.
0 ± 0.66.

On the other hand, the average body weight of the mice on the day of administration was 24 g ± 5% in each group, and the average body weight of mice on the day of this test (15 days after administration) was 22 g ± 5% only in the prednisolone group. , All other groups were 24 g ±
5%.

From these results, the samples A, L and H containing the ginseng extract extracted from the ginseng with water and the oyster husk powder (Borei powder, Japan Pharmaceutical Co., Ltd.) were almost the same as those of the group administered with blednisone. It can be seen that an equivalent atopic dermatitis inhibitory effect is observed, and that there are no side effects such as weight loss.

[0040]

The antiallergic composition of the present invention contains an aqueous extract of ginseng and an oyster hull. When these components are used simultaneously, a unique synergistic action is obtained, Demonstrates an excellent antiallergic effect on animals, including animals. In particular, the antiallergic composition of the present invention exerts an excellent effect in preventing and alleviating atopic dermatitis symptoms in infants and the like.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI theme coat ゛ (Reference) A61P 17/00 A61P 17/00 37/08 37/08 F term (Reference) 4B018 MD54 MD75 ME07 MF01 4C087 AA01 AA02 BB16 CA03 MA02 MA41 MA44 MA52 NA14 ZB13 4C088 AB18 AB40 AC13 AD08 BA09 CA05 CA11 MA41 MA52 NA14 ZB13

Claims (6)

[Claims] 1. An antiallergic composition for preventing or alleviating the symptoms of allergic diseases, comprising an aqueous extract of ginseng and oyster shells. 2. The ginseng of claim 1, wherein the ginseng is ginseng.
The antiallergic composition according to the above. 3. The antiallergic composition according to claim 1, wherein the allergic disease is atopic dermatitis. 4. The method according to claim 1, wherein the allergic disease is an allergic disease involving type I allergy.
The antiallergic composition according to the above. 5. The antiallergic composition according to claim 4, wherein the allergic disease associated with type I allergy is atopic dermatitis. 6. The weight ratio of the aqueous extract of ginseng to the oyster shell is such that the oyster shell is 50 to 1000 parts by weight based on 100 parts by weight of the solid content of the aqueous extract of ginseng.
An antiallergic composition according to any one of claims 1 to 5.